The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer  by Morgensztern, Daniel et al.
ORIGINAL ARTICLE
The Effect of FDG-PET on the Stage Distribution of
Non-small Cell Lung Cancer
Daniel Morgensztern, MD,*† Boone Goodgame, MD,* Maria Q. Baggstrom, MD,* Feng Gao, PhD,‡
and Ramaswamy Govindan, MD*
Purpose: To study the impact of 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) on stage distribution and survival
for patients with newly diagnosed non-small cell lung cancer
(NSCLC).
Methods: We searched the Barnes-Jewish Hospital/Washington
University School of Medicine database for patients with non-small
cell lung cancer (NSCLC) diagnosed between January 1, 1990 and
December 31, 2004. Since the use of FDG-PET increased in our
institution in the year 2000, patients were subdivided into those
diagnosed before or after January 1, 2000. We compared the stage
distribution of NSCLC before and after the year 2000. We also
compared the survival for patients diagnosed between 2000 and
2004 staged with or without FDG-PET.
Results: We identified 6118 patients diagnosed with NSCLC, with
3765 (61%) diagnosed before the year 2000 and 2362 (39%)
thereafter. The use of FDG-PET was significantly increased after the
year 2000 (37% versus 7%, p  0.001) and there was a significant
increase in the proportion of stage IV patients (30–37%, p  0.001)
with an associated decrease in stages I and III. Median overall
survival was increased in all patients with stage IV disease diag-
nosed after the year 2000 (5.8 months versus 4.5 months). Patients
with stage III or IV disease staged with FDG-PET scan also had
improved survival compared with those undergoing conventional
staging
Conclusion: The increased use of FDG-PET was associated with a
stage migration in patients with NSCLC, which may partially
account for improvements in survival as compared with historical
controls.
Key Words: PET, Outcomes, Non-small cell lung cancer, Staging,
Stage distribution, Population.
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Lung cancer is the second most common malignancy in theUnited States with an estimated 213,380 new patients
diagnosed in 2007, and the leading cause of cancer mortality
with 162,460 deaths projected for the same year.1 Non-small
cell lung cancer (NSCLC) accounts for approximately 86% of
the total number of lung cancer cases.2
Virtually all patients with known or suspected NSCLC
undergo a computed tomography (CT) of the chest and upper
abdomen including liver and adrenal glands as the initial
anatomic imaging modality of choice, followed by bone scan
and brain imaging in selected cases.3 Although CT is useful
in evaluating the primary tumor size and location, it has
limited ability to differentiate between benign and malignant
lesions or tumor and atelectasis. It is also not a reliable
noninvasive modality for the evaluation of mediastinal ade-
nopathy.4 Whole body positron-emission tomography (PET)
with 18F-fluorodeoxyglucose (FDG) has an established role in
the staging of lung cancer patients.
Although FDG-PET is widely considered to be more
accurate than CT scan for both locoregional and metastatic
disease, there have been no population-based studies evalu-
ating its effect on stage distribution among patients with
NSCLC. We hypothesized that a more frequent use of PET
would increase the relative proportion of stage IV disease at
the time of diagnosis because of an increased identification of
distant metastatic sites. A secondary objective of the study
was to determine if the stage-specific survival of NSCLC had
changed because of earlier identification of metastatic dis-
ease. We performed a retrospective analysis of patients seen
at our institution to evaluate variations in stage frequency and
survival between patients diagnosed before and after the
widespread availability of this imaging technique.
PATIENTS AND METHODS
We identified all patients with NSCLC diagnosed at our
institution between January 1, 1990 and December 31, 2005
using the hospital tumor registry. This registry (Barnes-
Jewish Hospital Oncology Data Services) is approved by the
American College of Surgeons. Tumor registrars are certified
and responsible for collecting the required data elements for
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all patients with cancer from review of the medical record.
All available records, including but not limited to, clinic
charts, inpatient charts, radiology reports, and pathology
reports are abstracted into the tumor registry database.
All patients diagnosed with NSCLC were included in
this study and were staged according to the updated American
Joint Committee on Cancer, 6th edition. Pertinent data were
obtained from the tumor registry database and included de-
mographic information, date of diagnosis, tumor size, histo-
logic subtypes, survival, and record of FDG-PET imaging.
Because of the widespread availability of FDG-PET imaging
in our institution since 2000, patients were grouped by date of
diagnosis, either before or after January 1, 2000. This study
was approved by the Human Studies Committee at Washing-
ton University School of Medicine. Our hypothesis was
that the standard use of FDG-PET would lead to an early
detection of metastatic disease, causing a shift in the stage
distribution.
All statistical comparisons were performed with the
two-sided 2 test or t test as appropriate. Survival time was
defined as time from the date of initial diagnosis to death of
any causes, and those alive were censored at the time of last
contact. Overall survival was estimated using the Kaplan-
Meier product limit method and compared using logrank test.
A p value under 0.05 was used to indicate significance and all
statistical tests were two-sided.
RESULTS
We identified 6118 consecutive patients between Jan-
uary 1, 1990 and December 31, 2005 (Table 1). There were
3756 patients diagnosed before January 1, 2000 (cohort 1)
and 2362 thereafter (cohort 2). Final stage was assigned
according to pathologic findings in 2305 patients and clini-
cally in 3813 patients. Approximately 2% of patients had an
unknown stage in both groups.
Significant changes in the demographic patterns in-
cluded an increased proportion of females (42–46%, p 
0.005) and patients younger than 60 (26–29%, p  0.013). A
markedly increased proportion of tumors were identified as
non-small cell lung cancer not otherwise specified, (14–25%,
p  0.001) with a concomitant sharp decrease in squamous
cell carcinomas (33–23%) in the more recent cohort of
patients.
The use of FDG-PET imaging increased in the late
1990s and was obtained in 19% of patients diagnosed in
1999. We observed a steady increase in the use of FDG-PET
since the turn of the century from 28% of patients in 2000 to
46% of patients in 2004 (Figure 1). In total, FDG-PET
imaging was performed in 273 patients (7%) in cohort 1 and
799 patients (36%) in cohort 2 (p  0.001). FDG-PET was
used more commonly in early stage disease, where a change
of stage could significantly affect the management, than in
locally advanced or known metastatic disease (Figure 2).
There were significant changes in the distribution of
stages I through IV between the two cohorts (p  0.001).
Patients with stage IV disease at the time of diagnosis
increased from 30% in cohort 1 to 37% in cohort 2 (p 
0.001). This increase in stage IV disease in cohort 2 was
accompanied by a reciprocate decrease in the percentage of
patients diagnosed with stage I (29–25%) and stage III
disease (31–27%) (Figure 3).
Because changes in referral patterns to our institution
could potentially confound our results (i.e., referrals to med-
ical oncology increasing out of proportion to referrals to
thoracic surgery), we compared referral rates between de-
cades. The proportion of patients diagnosed elsewhere and
referred to us for treatment (identified as “referrals”) in-
creased after 2000 (26–38%, p 0.001). Although there was
a disproportionate increase in the number of referrals for
patients with stage IV NSCLC (increased by 12%) compared
with all the other stages (increased by 8%), this difference
was not statistically significant (p  0.22). When only pa-
tients diagnosed and treated at our institution were analyzed,
rates of stage IV disease were still significantly increased
after 2000 compared with the previous study period (32–
36%, p  0.001).
The overall median survival was 13 months with a
1-year survival of 35%. Although there were no significant
changes in overall survival for all stages combined, patients
with NSCLC stage IV diagnosed between the years 2000 and
TABLE 1. Patient Characteristics by Date of Diagnosis
Variables
1990–1999 2000–2005
pn Percent n Percent
Total subjects 3756 61 2362 39
Age at diagnosis 0.005
Median 67 67
Age 60 974 26 681 29
Age 75 834 22 555 23
Gender 0.005
Male 2164 58 1275 54
Female 1592 42 1087 46
Ethnicity 0.536
White 2870 76 1834 78
Black 848 23 505 21
Stage 0.001
1 1080 29 612 26
2 328 9 209 9
3 1130 30 618 26
4 1142 30 877 37
Clinical staging only 2367 63 1446 61
Unknown 76 2 46 2
Size
Median 3.5 3.5 0.995
PET 267 7 865 37 0.001
Clinical Dx only
(no tissue)
169 4 114 5 0.553
Histologic subtype 0.001
Adenocarcinoma 1437 38 912 39
Squamous 1259 34 556 24
Bronchioloalveolar 116 3.1 88 3.7
Other subtypes 274 7.3 107 4.5
NSCLC unspecified 514 13.7 593 25.1
PET, positron emission tomography; Dx, diagnosis.
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2004 had increased median overall survival (4.5–5.8 months,
p  0.001) and 1-year survival (21–28%) compared with
those diagnosed between 1990 and 1999 (Figure 4). This
improvement remained significant after adjusting for age,
gender, and histology (p 0.0001). There were no difference
in survivals between patients with stage IV diagnosed be-
tween the years 1990–1994 and 1995–1999 (p 0.114) (data
not shown).
Among patients with stage IV disease diagnosed be-
tween 2000 and 2004, there was a significant improvement in
outcomes for those staged by PET compared with patients
without PET, with increased overall median survival (4.5–8.5
months), 1-year survival (24.8–38.5%), and 2-year survival
rates (9.2–19.9%) (p  0.0001) (Figure 5A). A similar im-
provement was observed in patients with stage III diagnosed
in the same period, with increased median overall survival
(10.3–22 months), 1-year survival (46–71%), and 2-year
survival (25.9–43.8%) (p  0.0001) (Figure 5B). The im-
provement in survival for stages I and II was small and not
statistically significant (data not shown).
DISCUSSION
Data from the National Cancer Data Base including
590,292 patients showed essentially no significant changes in
stage distribution between the years 1988 and 1995.5,6 During
this period, there were no significant advances in imaging
modalities for NSCLC staging because, despite improve-
ments in CT scan resolution, its accuracy remained essen-
tially unchanged.
FDG-PET imaging is a relatively new noninvasive
diagnostic technique, which has been used with increased
frequency in the diagnosis and staging of lung cancer. Con-
ventional anatomic imaging studies frequently lead to under-
staging of NSCLC patients and several studies have evaluated
the potential benefit from the use of FDG-PET in this setting.
A large pooled analysis compared the accuracy of CT imag-
ing and FDG-PET imaging in mediastinal staging.7 Among
3438 patients from 18 studies staged with CT scan, sensitivity
and specificity of mediastinal lymph node were 57% and
82%, respectively. The addition of FDG-PET improved the
sensitivity and specificity to 84% and 89%, respectively.
Overall, the prevalence of mediastinal disease increased from
28% in patients staged with CT to 32% in patients staged with
PET. Improved accuracy for FDG-PET in mediastinal staging
was also observed in a recent meta-analysis of 39 studies,
which showed improvements in both median sensitivity (85%
FIGURE 1. Rates of FDG-PET imaging at presentation and
rates of stage IV disease for all patients by year of diagnosis.
FIGURE 2. Rates of FDG-PET imaging at presentation,
grouped by stage and cohort.
FIGURE 3. Relative distribution of stages of disease at the
time of diagnosis, grouped by cohort.
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versus 61%) and specificity (90% versus 79%) for this im-
aging modality.8
Prospective studies with the use of FDG-PET have
shown the detection of unsuspected distant metastases in 11
to 16.5% of patients with newly diagnosed NSCLC, changes
in stage in 27 to 62% of patients, and changes in medical
management in 25 to 37% of patients.9–11 As expected,
changes in staging were more frequent because of the detec-
tion of unsuspected distant lesions.
In one of the largest performed studies,12 FDG-PET
was significantly better than CT for the detection of N1
disease (42% versus 13%), mediastinal adenopathy (58%
versus 32%), and metastatic disease or second primary ma-
lignancy, which were detected in 6.3% of the patients. Over-
all, FDG-PET allowed the identification of advanced and
unresectable disease (stages IIIA–IV) in 43 of 303 patients
(14.2%), thereby avoiding unnecessary thoracotomy. In a
recent randomized multicenter trial,13 the addition of FDG-
PET to standard work-up, improved the selection of surgi-
cally curable patients by decreasing the rate of futile thora-
cotomy from 43 to 21%.
Because of the improved accuracy of FDG-PET in the
staging of patients with NSCLC, it is likely that the wide-
spread use of this imaging technique has caused significant
stage migration, although this finding has not been published
in any longitudinal, population-based study. The current hos-
pital-based cohort study has documented a change in the
distribution of stages since the availability of FDG-PET
imaging, with an increase in the proportion of stage IV
disease and a concomitant decrease in the proportion of
stages I and III disease.
We also identified a small but significantly improved
survival in patients with stage IV NSCLC treated at our
institution since 2000. This improvement may be attributed to
the new developments in supportive care and chemotherapy
agents, particularly after the proven benefit from second-line
therapy14,15 and the introduction of targeted agents such as
erlotinib.16 Nevertheless, an alternative explanation is the
FIGURE 4. Overall survival for stage IV NSCLC
patients grouped by cohort.
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FIGURE 5. A, Overall survival for stage IV pa-
tients according to the use of PET. B, Overall
survival for stage III patients according to the
use of PET.
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“Will Rogers phenomenon,” an apparent paradox obtained
when moving an element from one set raises the average
values for both the donor and the recipient sets.17 With the
introduction of new diagnostic procedures, the upstaging of
patients with minimal metastatic disease improves the overall
prognosis of the donor earlier stages by eliminating those
with true metastatic disease. The recipient set, consisting of
patients with advanced stage, benefits from the addition of
patients with smaller tumor burden, whose prognosis is pre-
dictably better than in those with a large volume of disease
and easily identified by conventional staging techniques.
However, although the prognosis improves within each stage,
it does not change for the group as a whole. One would also
expect our data to show an improved survival in stages I and
III. However, the improvement was small, and not statisti-
cally significant. In a recent study, Gauger et al. evaluated the
recurrence patterns in patients with clinical stage I NSCLC
staged with FDG-PET.18 Among the 196 patients, there were
40 (20%) recurrences. The estimated overall survival at 5
years, between 65% and 70%, is modestly improved in
comparison with historical controls.19
In a preliminary analysis to evaluate potential stage
migration in a larger population, we recently reported the
results from a National Cancer Data Base survey in 510,942
NSCLC patients from 1998 to 2003.20 The percentage of
stage IV remained relatively constant until the year 2000,
when it increased from 35.7 to 38.9%. Subsequent years
showed significantly smaller variation and the curve seems to
be reaching a plateau, suggesting that an event occurring
between the years 2000 and 2001 may be the main factor
responsible for the stage migration. This period coincides
with the widespread use of PET imaging. Subtle changes in
stage may result in increased survival for both early and
advanced disease. Caution should be used when comparing
results from new studies with historical controls, because
improved outcomes may reflect, at least in part, the effects of
stage migration.
In summary, we have demonstrated that the introduc-
tion of FDG-PET imaging in the staging of NSCLC is
associated with a significant change in the stage distribution,
with an increased percentage of patients diagnosed with
metastatic disease. To our knowledge, this is the first longi-
tudinal study addressing this question which has been pub-
lished to date.
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